Iconix Brand Group, Inc., a brand management company, owns, licenses, and markets a portfolio of consumer brands across the womenÂ’s, menÂ’s, entertainment, and home industries in the United States and internationally. The company has market cap of $75.91 million. The companyÂ’s brand portfolio includes Candie's, Bongo, Joe Boxer, Rampage, Mudd, Mossimo, London Fog, Ocean Pacific/OP, Danskin/Danskin Now, Rocawear/ Roc Nation, Cannon, Royal Velvet, Fieldcrest, Charisma, Starter, Waverly, Zoo York, Umbro, Lee Cooper, Ecko Unltd/Mark Ecko Cut & Sew, Strawberry Shortcake, and Artful Dodger brands. It currently has negative earnings. It also owns interests in the Material Girl, Peanuts, Ed Hardy, Truth or Dare, Modern Amusement, Buffalo, Nick Graham, Hydraulic, and Pony Brands.
Among 2 analysts covering CRISPR Therapeutics (NDAQ:CRSP), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. CRISPR Therapeutics has $23.50 highest and $16 lowest target. $19.75’s average target is -6.62% below currents $21.15 stock price. CRISPR Therapeutics had 2 analyst reports since March 28, 2017 according to SRatingsIntel. The rating was initiated by Chardan Capital Markets on Tuesday, March 28 with “Buy”. The firm has “Hold” rating by Suntrust Robinson given on Friday, July 14.
Permit Capital Llc holds 3.73% of its portfolio in Iconix Brand Group, Inc. for 1.11 million shares. Huber Capital Management Llc owns 2.89 million shares or 0.9% of their US portfolio. Moreover, Smith Graham & Co. Investment Advisors Lp has 0.71% invested in the company for 1.19 million shares. The Quebec – Canada-based Van Berkom & Associates Inc. has invested 0.55% in the stock. Malaga Cove Capital Llc, a California-based fund reported 163,699 shares.
The stock decreased 4.32% or $0.06 during the last trading session, reaching $1.33. About 1.71M shares traded. Iconix Brand Group, Inc. (ICON) has declined 13.52% since December 23, 2016 and is downtrending. It has underperformed by 30.22% the S&P500.
Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on March, 9. They expect $-0.74 EPS, down 85.00% or $0.34 from last year’s $-0.4 per share. After $-0.62 actual EPS reported by CRISPR Therapeutics AG for the previous quarter, Wall Street now forecasts 19.35% negative EPS growth.